GETLIN LAWRENCE W 4

4 · ProUroCare Medical Inc. · Filed Aug 13, 2012

Form 4

Period: 2012-08-09

Director

Transactions

Award
Stock Options
2012-08-09+25,000→ 25,000 total
Exercise: $0.60Exp: 2019-08-09→ Common stock, $0.00001 par value (25,000 underlying)

Holdings

Convertible Note
Exercise: $1.10Exp: 2012-08-28→ Common stock, $0.00001 par value
Stock Options
Exercise: $0.87Exp: 2018-08-09→ Common stock, $0.00001 par value (28,736 underlying)
28,736
Common stock, $0.00001 par value
51,178
Stock Options
Exercise: $0.92Exp: 2018-06-27→ Common Stock, $0.00001 par value (2,265 underlying)
2,265
Convertible notes
Exercise: $1.30Exp: 2013-09-15→ Common Stock, $0.00001 par value (19,231 underlying)

Footnotes (4)

[F1]Currently exercisable.
[F2]Annual option award pursuant to the Issuer's compensation policy for Directors upon their re-election to the Board of Directors. The seven-year options vest ratably over 12 months.
[F3]On December 1, 2011, the reporting person and the Company executed a convertible promissory note in the principal amount of $5,200 with a maturity date of Ferbruary 28, 2012. The maturity date of the note was subsequently amended to August 28, 2012. The principal amount and interest accruing at a rate of 10% per year are convertible into common shares at $1.10 per share at any time through the maturity date. The number of shares to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within 2 business days after conversion. The issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rules 16b-3(d).
[F4]On June 20, 2012, the issuer issued 9,000 shares to the reporting person in lieu of cash for $9,000 of consulting fees due to the reporting person and 6,000 shares issued in lieu of cash for directors' fees. The issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rules 16b-3(d).

Documents

1 file